Clinical Trial Success and Regulatory Approval Risks: The success of RegenXBio's product candidates, particularly RGX-314, depends on favorable results from ongoing and future clinical trials and subsequent regulatory approvals. Failure to meet primary or secondary endpoints, or the emergence of unexpected safety concerns, could significantly delay or prevent product commercialization.

Intense Competition in Gene Therapy Market: The gene therapy and ophthalmology markets are highly competitive. Many pharmaceutical and biotechnology companies are developing or marketing treatments for wet AMD, diabetic retinopathy, and other target indications. RegenXBio's products may not be able to compete effectively against existing or future therapies.

Intellectual Property Protection Challenges: RegenXBio's ability to protect its proprietary technology, including the NAV Technology Platform and product candidates, through patents and other intellectual property rights is vital. Challenges to their patents or the inability to obtain new patent protection could erode their competitive position and allow competitors to develop similar products.